25B-NBOH

25B-NBOH (2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine) is a potent synthetic psychedelic of the substituted phenethylamine family, structurally related to 2C-B and belonging to the NBOH series — a class of compounds characterized by the substitution of a 2-hydroxybenzyl (NBOH) group on the terminal nitrogen of the phenethylamine scaffold. First synthesized in 2012 as part of pharmacological research into 5-HT2A receptor ligands, 25B-NBOH is active at microgram-range doses and produces a psychedelic experience broadly similar to 2C-B.

The NBOH series was developed as a research alternative to NBOMe compounds, primarily for radioligand binding studies. Like NBOMe analogs, NBOH compounds are only active via sublingual or buccal routes — they are essentially inactive when swallowed, as rapid first-pass metabolism destroys the active form. This means any legitimate blotter must be held under the tongue or against the cheek. Compounds that require swallowing and claim to be NBOH should be regarded with suspicion.

25B-NBOH is considered to carry significantly less acute fatality risk than 25B-NBOMe. No confirmed fatalities from 25B-NBOH alone have been documented in the scientific literature. However, this should not imply safety: the compound is active at doses of 250–750 μg, vasoconstriction is a consistent effect, the dose-response curve is steep, and the absence of documented fatalities partly reflects that NBOH compounds are far less prevalent than their NBOMe counterparts. Harm reduction principles identical to those applied to NBOMe compounds — reagent testing, accurate dosing from solutions, avoiding redosing, avoiding combination with stimulants or vasoconstrictors — are essential.